Our work underscores that previous, unsuccessful clinical trials appropriately assessed the significance of IL‐6 signaling in PCa progression, but may have failed in their approach to target IL‐6 or IL‐6 signal transduction factors JAK/STAT (Buchert et al., 2016; Dorff et al., 2010; Fizazi et al., 2012; Plimack et al., 2013). The gene discussed is IL6; the disease is posterior cortical atrophy.